See more : Molecular Partners AG (MOLN) Income Statement Analysis – Financial Results
Complete financial analysis of Volpara Health Technologies Limited (VPAHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Volpara Health Technologies Limited, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- X-FAB Silicon Foundries SE (XFABF) Income Statement Analysis – Financial Results
- Tah Tong Textile Co., Ltd. (1441.TW) Income Statement Analysis – Financial Results
- Mendelson Infrastructures & Industries Ltd. (MNIN.TA) Income Statement Analysis – Financial Results
- Aspen Insurance Holdings Limited (AHL-PE) Income Statement Analysis – Financial Results
- Nordex SE (NRDXF) Income Statement Analysis – Financial Results
Volpara Health Technologies Limited (VPAHF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.volparahealth.com
About Volpara Health Technologies Limited
Volpara Health Technologies Limited provides breast imaging analytics software products in New Zealand. The company offers Volpara Analytics, a software that optimize breast cancer screening operations; Volpara Live, which provides instant patient-based image quality feedback; Volpara Lung, a patient management software that streamlines lung screening workflow; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses TC8 to calculate patients' risk of developing breast cancer; Volpara Risk Pathways, a program for identifying and managing high-risk breast cancer screening patients; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products. In addition, the company provides TruDensity, a Volpara clinical function; TruPGMI, a Volpara clinical function, which uses artificial intelligence to automatically and objectively assess the positioning of the patient and resulting image quality; TruPressure, a Volpara clinical function, which determines whether the compression pressure applied by the radiographer is in the sweet spot that yields quality images, minimal radiation exposure, and the least discomfort; and TruRadDose, a Volpara clinical function which analyses the radiation dose delivered to patients based on their breast density. It operates in North America, the Asia Pacific, Europe, the Middle East, and Africa. Volpara Health Technologies Limited has a strategic relationship with RevealDx. The company was incorporated in 2009 and is headquartered in Wellington, New Zealand.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.77M | 24.27M | 18.13M | 12.32M | 5.48M | 2.64M | 1.68M | 0.00 |
| Cost of Revenue | 2.47M | 2.13M | 1.55M | 1.73M | 835.09K | 779.64K | 621.00K | 0.00 |
| Gross Profit | 30.30M | 22.14M | 16.57M | 10.59M | 4.65M | 1.86M | 1.06M | 0.00 |
| Gross Profit Ratio | 92.45% | 91.23% | 91.43% | 85.98% | 84.77% | 70.48% | 63.02% | 0.00% |
| Research & Development | 16.55M | 15.65M | 13.01M | 10.63M | 5.41M | 2.95M | 2.10M | 0.00 |
| General & Administrative | 12.45M | 11.39M | 11.51M | 11.59M | 2.92M | 3.06M | 3.05M | 0.00 |
| Selling & Marketing | 14.29M | 13.12M | 11.28M | 12.92M | 8.08M | 5.05M | 4.77M | 0.00 |
| SG&A | 26.74M | 24.52M | 22.79M | 24.51M | 11.00M | 8.11M | 7.82M | 0.00 |
| Other Expenses | 2.52M | 2.99M | 1.39M | 2.15M | 113.01K | 661.28K | -124.20K | 0.00 |
| Operating Expenses | 48.42M | 44.50M | 38.63M | 37.32M | 16.70M | 11.11M | 9.94M | 0.00 |
| Cost & Expenses | 50.89M | 46.63M | 40.19M | 39.05M | 17.54M | 11.89M | 10.57M | 0.00 |
| Interest Income | 174.11K | 160.80K | 571.01K | 751.68K | 445.32K | 255.50K | 247.49K | 0.00 |
| Interest Expense | 354.77K | 133.84K | 134.03K | 72.15K | 56.50K | 4.70K | 2.74K | 0.00 |
| Depreciation & Amortization | 5.13M | 4.33M | 2.84M | 2.18M | 296.88K | 56.36K | 24.66K | 16.56K |
| EBITDA | -6.83M | -13.85M | -16.67M | -19.49M | -11.85M | -8.22M | -9.11M | 0.00 |
| EBITDA Ratio | -15.76% | -43.47% | -79.58% | -157.92% | -198.88% | -311.27% | -518.81% | 0.00% |
| Operating Income | -10.30M | -14.88M | -17.26M | -21.64M | -11.20M | -8.28M | -8.74M | 0.00 |
| Operating Income Ratio | -31.42% | -61.31% | -95.22% | -175.64% | -204.30% | -313.41% | -520.28% | 0.00% |
| Total Other Income/Expenses | 1.17M | 3.22M | 2.16M | 2.24M | 882.30K | 760.65K | 395.68K | 0.00 |
| Income Before Tax | -10.65M | -15.01M | -17.40M | -21.71M | -11.26M | -8.28M | -8.74M | 0.00 |
| Income Before Tax Ratio | -32.50% | -61.86% | -95.96% | -176.23% | -205.33% | -313.58% | -520.45% | 0.00% |
| Income Tax Expense | -1.48M | 266.75K | -1.34M | -1.89M | -11.49K | 665.98K | -121.46K | 0.00 |
| Net Income | -9.17M | -15.28M | -16.05M | -19.83M | -11.24M | -8.28M | -8.74M | 0.00 |
| Net Income Ratio | -27.99% | -62.96% | -88.56% | -160.90% | -205.12% | -313.58% | -520.45% | 0.00% |
| EPS | -0.04 | -0.06 | -0.06 | -0.09 | -0.06 | -0.06 | -0.07 | 0.00 |
| EPS Diluted | -0.04 | -0.06 | -0.06 | -0.09 | -0.06 | -0.06 | -0.07 | 0.00 |
| Weighted Avg Shares Out | 252.20M | 251.38M | 247.26M | 210.14M | 176.39M | 146.03M | 128.89M | 63.93M |
| Weighted Avg Shares Out (Dil) | 252.20M | 251.38M | 247.26M | 210.14M | 176.39M | 146.04M | 128.89M | 63.93M |
Volpara Health breast density and mammography quality software highlighted in new peer-reviewed research
Volpara Health enters agreement to be acquired by Lunit, Inc.
Volpara Health and LehYup Partner on Cancer Risk Assessment Services at RSNA 2023
Volpara Health ushers in new era of breast imaging at RSNA 2023
Volpara Health partners with Trees that Count to offset carbon emissions
Source: https://incomestatements.info
Category: Stock Reports